Antitope Announces Antibody Research Agreement with Elusys Therapeutics, Inc

Antitope Announces Antibody Research Agreement with Elusys Therapeutics, Inc

15th May 2006 Antitope Ltd., a leader in the development of Composite Human Antibody™ technology for the generation of therapeutic antibodies of entirely human origin announced a research agreement with Elusys Therapeutics, Inc. Under the research agreement, Antitope will generate a composite human antibody from a murine monoclonal antibody targeting an antigen selected by Elusys.

"We are extremely pleased that Elusys has chosen Antitope's Composite Human Antibody™ technology" said Matthew Baker, Chief Executive Officer and Founder of Antitope Ltd "Our collaboration with Elusys represents an excellent opportunity for Antitope to showcase its innovative antibody engineering technology."

About Antitope

Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing as well as the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary Composite Human Antibody™ technology builds upon previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies /proteins through humanization and DeImmunisation technologies. Antitope is a privately held company and has established commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk

About Elusys

Elusys is a privately held biopharmaceutical company focused on the development of targeted anti infective therapeutics using proprietary HP Antibodies. For more information on Elusys visit www.elusys.com